Skip Navigation

European Heart Journal 2002 23(20):1632; doi:10.1053/euhj.2002.3299
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Borja, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borja, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letters To The Editor

Enoxaparin in unstable coronary artery disease

J. Borja

Medical Department, Pharmacia Spain, S.A. Barcelona, Spain

References

  1. Cannon CP. Enoxaparin in ST elevation M I—a bright future. Eur Heart J. 2002;23:591–592[Free Full Text]
  2. Michalis LK, Papamichail N, Katsouras CS. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET Study). J Am Coll Cardiol. 2001;37:365A
  3. Klein W, Buchwald A, Hillis SE, Monrad S. For the FRIC investigators: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery diseasde. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 1997;96:61–68[Abstract/Free Full Text]
  4. Eur Heart J. 1999;20:1553–1562[Abstract/Free Full Text]
  5. Cohen M, Demers C, Gurfinkel EP. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447–452[Abstract/Free Full Text]
  6. Antman EM, Mc Cabe CH, Gurfinkel EP. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation. 1999;100:1593–1601[Abstract/Free Full Text]
  7. Eikelboom JI, Anand SS, Malmberg K. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndromes without ST elevation: a meta-analysis. Lancet. 2000;355:1936–1942[CrossRef][ISI][Medline]
  8. Holdright D, Patel D, Cunningham D. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol. 1994;24:39–45[Abstract]
  9. Bozovich GE, Gurfinkel EP, Antmann E. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. Am Heart J. 2000;140:637–642[CrossRef][ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Borja, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borja, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?